Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Talecris Biotherapeutics Holdings Corp. (TLCR) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/01/2011 PRN Grifols and Talecris Biotherapeutics Announce the FTC Has Accepted the Consent Agreement for Public Comment
05/02/2011 PRN Grifols and Talecris Biotherapeutics Announce the Signing of a Consent Agreement with FTC Staff
03/04/2011 PRN Talecris Biotherapeutics Announces Record Date for 2011 Annual Meeting of Shareholders
03/04/2011 PRN Grifols and Talecris Announce the Outside Date of Their Merger Agreement has been Extended to June 30, 2011
03/03/2011 PRN Talecris Biotherapeutics Receives EU Orphan Drug Designation for Plasmin (Human) as a Treatment for Acute Peripheral Arterial Occlusion
02/15/2011 PRN NASDAQ Removes TLCR From Biotechnology Index Pending FTC Decision on Grifols Acquisition
02/14/2011 PRN Talecris Shareholders Approve Merger with Grifols During Special Meeting of Shareholders
02/08/2011 PRN Talecris Biotherapeutics to Report Fourth Quarter and Full Year 2010 Financial Results
07/16/2010 PRN Talecris Biotherapeutics to Report Second Quarter 2010 Financial Results
07/08/2010 PRN Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
05/17/2010 PRN Talecris Added to NASDAQ Biotechnology Index
05/06/2010 PRN Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
04/26/2010 PRN Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
04/20/2010 PRN Talecris Biotherapeutics Announces Results of Annual Stockholders' Meeting
04/12/2010 PRN Gamunex(R) is the Preferred IGIV Therapy of Neurologists

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy